Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

@article{Giles2009ClassEO,
  title={Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia},
  author={F J Giles and M E O'Dwyer and Ronan T Swords},
  journal={Leukemia},
  year={2009},
  volume={23},
  pages={1698-1707}
}
Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the efficacy and safety profile of each agent when choosing the best therapeutic option for individual patients. Each agent targets tyrosine kinases within the cell uniquely to cause the… 

Figures and Tables from this paper

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia
TLDR
This review summarizes the biologic mechanism of BCR-ABL1 inhibition and differential target spectra, and related off-target effects of each TKI.
Off-Target Effects of BCR-ABL and JAK2 Inhibitors
TLDR
Understanding the off-target binding and effects upon signaling pathway of the agents approved for the treatment of MPN will empower the clinician to adroitly select pharmacotherapy, predict toxicities, and utilize these agents in clinical practice for indications beyond MPN.
Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis
TLDR
The efficacy and safety results of various TKI and non-TKI modalities and other novel pharmacological agents in the therapy of CML are compared.
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
TLDR
Clinical data has guided mechanistic studies toward alteration of platelet functions and atherosclerosis development, which might be secondary to metabolism impairment, suggesting a potentially protecting cardiovascular effect of this treatment in patients with BCR-ABL CML.
Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events
TLDR
An overview of the efficacy and safety of tyrosine kinase inhibitors approved for the treatment of CML, as well as recommendations for the management of key adverse events reported with these agents in clinical trials involving patients with CML are provided.
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
TLDR
The authors believe that monoclonal antibodies and immunotherapy should also be combined with TKIs and up-front chemotherapy for the successful treatment of ALL.
Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia
TLDR
As the first-line therapy of patients with newly diagnosed Ph+ CML-CP, nilotinib has higher rates of CCyR and MMR, lower rates of progression to AP or BC, and lower risk of CML related death when compared with imatinib.
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
TLDR
A profile of the adverse effects induced by nilotinib is reviewed, which shows some toxicities that are different from those of occurring during other BCR/ABL TKI treatments, such as cardiovascular toxicity.
Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use
TLDR
The authors evaluate comprehensively the adverse cardiovascular portfolio of small molecule TKIs, postulate their underlying mechanisms and offer recommendations regarding prevention and therapy of these toxicities.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 124 REFERENCES
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
TLDR
Two second-generation drugs, nilotinib and dasatinib, displaying increased potency against BCR-ABL were developed and comprehensive drug-protein interaction profiles by chemical proteomics for all 3 drugs were generated to predict potential side effects and novel medical uses.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
TLDR
STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.
TLDR
The results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Philadelphia-positive (Ph+) leukemia.
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
  • M. Mauro
  • Medicine, Biology
    Cancer control : journal of the Moffitt Cancer Center
  • 2009
TLDR
Treatment for CML should be individualized and, when resistance to imatinib can be predicted, therapy should be modified so that patients do not progress beyond chronic phase and respond as promptly and deeply as required to maximally reduce risk.
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
TLDR
The potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis is assessed.
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
TLDR
It is demonstrated for the first time that imatinib targets the macrophage colony-stimulating factor (M-CSF) receptor c-fms, identifying an additional biologic target to those already defined for Imatinib.
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
TLDR
The mechanism of action of imatinib in CML, the structural basis ofImatinib resistance, and the potential of second-generation BCR-ABL inhibitors to circumvent resistance are described.
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
TLDR
Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of d asatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL.
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
TLDR
In this review, the early characterisation and development of AMn107 is discussed, as is the current status of AMN107 in clinical trials for imatinib-resistant CML and Ph+ ALL.
...
1
2
3
4
5
...